Mechanisms of resistance to targeted therapy in non-small cell lung cancer: Strategies for modeling and combating acquired resistance
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Duisburg, Essen, Universität Duisburg-Essen, Dissertation, 2021
- Keyword
-
Therapeutics
Small cell lung cancer
- Event
-
Veröffentlichung
- (where)
-
Duisburg, Essen
- (who)
-
Universität Duisburg-Essen
- (when)
-
2021
- Creator
- Contributor
-
Schramm, Alexander
- DOI
-
10.17185/duepublico/75256
- URN
-
urn:nbn:de:hbz:464-20211222-081113-9
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ho, Cassandra Su Lyn
- Schramm, Alexander
- Universität Duisburg-Essen
Time of origin
- 2021
Other Objects (12)
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Combating antimicrobial resistance by targeting underexplored pathways
Combating resistance to xenobiotics : biolog. and chem. approaches
Metabolic Signals in Systemic Acquired Resistance
FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level
How civil society action can contribute to combating antimicrobial resistance
Combating bacterial resistance by combination of antibiotics with antimicrobial peptides
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Combating antimicrobial resistance by targeting underexplored pathways
Combating resistance to xenobiotics : biolog. and chem. approaches
Metabolic Signals in Systemic Acquired Resistance
FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level
How civil society action can contribute to combating antimicrobial resistance
Combating bacterial resistance by combination of antibiotics with antimicrobial peptides
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Combating antimicrobial resistance by targeting underexplored pathways
Combating resistance to xenobiotics : biolog. and chem. approaches
Metabolic Signals in Systemic Acquired Resistance
FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level
How civil society action can contribute to combating antimicrobial resistance